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ABSTRACT
Objective: To identify the key methodological issues in the construction of
population-level EuroQol 5-dimensions (EQ-5D)/time trade-off (TTO)
preference elicitation studies.
Method: This study involved three components. The ﬁrst was to identify
existing population-level EQ-5D TTO studies. The second was to illustrate
and discuss the key areas of divergence between studies, including the
international comparison of tariffs. The third was to portray the relative
merits of each of the approaches and to compare the results of studies
across countries.
Results: While most articles report use of the protocol developed in the
original UK study, we identiﬁed three key areas of divergence in the
construction and analysis of surveys. These are the number of health states
valued to determine the algorithm for estimating all health states, the
approach to valuing states worse than immediate death, and the choice of
algorithm. The evidence on international comparisons suggests differences
between countries although it is difﬁcult to disentangle differences in
cultural attitudes with random error and differences as a result of meth-
odological divergence.
Conclusions: Differences in methods may obscure true differences in
values between countries. Nevertheless, population-speciﬁc valuation sets
for countries engaging in economic evaluation would better reﬂect cultural
differences and are therefore more likely to accurately represent societal
attitudes.
Keywords: cost-utility analysis, EQ-5D, health economics methods,
health-related quality of life.
Introduction
Cost-utility analysis (CUA), where outcomes are measured in
terms of quality-adjusted life-years (QALYs), is the main
approach used to measure and value the impacts of treatments.
The US Panel on Cost-Effectiveness in Health and Medicine
recommends the use of QALYs [1]; the UK National Institute of
Health and Clinical Excellence has most commonly used CUA
[2,3] and has recently recommended that it should be the
preferred outcome measure; and CUA is increasingly used in
Australia in the evaluation of pharmaceuticals and medical ser-
vices. In the recently released PBAC guidelines, a preference
is expressed for the use of CUA [4].
While CUA is simple in concept, it presents challenges in
practice. QALYs are designed to allow comparisons across inter-
ventions with disparate outcomes across different health-care
conditions and population groups. Eliciting valuations for all
health states that may be relevant to a disease or intervention is
time consuming and costly, and comparison of valuations across
interventions and diseases requires comparability of methods.
Multiattribute utility instruments (MAUIs), which comprise a
generic descriptive quality of life instrument and a scoring algo-
rithm that covers all health states described by the instrument
(e.g., the EQ-5D, the Short Form-6 dimensions (SF-6D), Health
Utilities Index, and Assessment of Quality of Life), have facili-
tated comparability [5,6]. The scoring algorithm for these instru-
ments is usually generated from a stated preference experiment,
typically time trade-off (TTO), standard gamble conducted in a
population sample The key advantage of the MAU approach is
that it provides community-based valuation of health states for
patients who are experiencing the state.
The role of MAUIs in economic evaluation is increasing. For
example, the National Institute of Clinical Excellence has recom-
mended the use of the EQ-5D, and the Pharmaceutical Beneﬁts
Advisory Committee in Australia has stated a preference for
utility weights generated from the use of a MAUI in a clinical
trial setting (without specifying a preference for a particular
MAUI). Nevertheless, recent reviews have noted that there are
signiﬁcant differences in the performance of different MAUIs [7],
which can be attributed to differences in the dimensions covered
by the instruments, differences in preference elicitation tech-
niques, and differences in the methods used to derive the scoring
algorithm. These differences can have signiﬁcant impact on valu-
ations of health states and the resulting cost-effectiveness of
interventions [8]. There has been relatively little critical appraisal
of the methods of development of MAUIs scoring algorithms. In
this article, we examine these issues by considering the EQ-5D
[9]. We chose the EQ-5D because it is widely used, and there
have been a number of different studies undertaken to develop
country-speciﬁc scoring algorithms. Because the focus of this
review is on one MAUI, we do not consider the psychometric
aspects of the instrument but, rather, focus on the methods for
development of the scoring algorithm. Many of the issues we
raise are relevant to other MAUIs.
Overview of the EQ-5D
The EQ-5D is a tool developed by the EuroQol group (Rotterdam,
The Netherlands) (www.euroqol.org) and has ﬁve dimensions
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intended to represent the major areas in which health changes can
manifest. These areas are mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression. Each dimension con-
tains three levels, classiﬁed as “No Problems,” “Some Problems,”
and “Extreme Problems.” Details are shown in Table 1. Thus,
there are 35 = 243 potential states in the descriptive system. The
TTO approach is used to value a selection of these states and then
to impute values for the remainder using simple regression. The
use of TTO for valuing EQ-5D states is well described in other
works [10,11]. For states considered to be preferable to immediate
death, a respondent is faced with a choice between 10 years of a
particular chronic health state deﬁned in EQ-5D space with a
period of x years in full health. The aim of the TTO is to identify
a value of x for which the individual is indifferent to the choice.
The value for the better-than-death health state is deﬁned as x/10.
Regarding Table 1, it should also be noted that we will treat
health states with the same levels as identical throughout this
article (e.g., health state 12321 is the same irrespective of lan-
guage). As of March 2009, the EQ-5D has been translated into
100 different languages (with a further 24 awaiting ratiﬁcation).
The comparability of versions is a reasonable assumption because
all translations are reviewed by EuroQol Group members and
ratiﬁed by the EuroQol Group Executive Committee. The Euroqol
Web site states that translation consists of two forward transla-
tions of the EQ-5D English source version, two back translations,
lay assessment, and the production of a full report describing each
stage of the process (http://www.euroqol.org).
Our analysis of this EQ-5D/TTO approach involves two
strands: ﬁrst, we look at how to elicit societal valuations for
EQ-5D states under the York Research Group on the Measure-
ment and Valuation of Health TTO protocol [9]. We begin by
identifying some key themes and issues that run across the
population valuation studies. Then, we look at international
comparisons and discuss whether it is necessary to provide
nationality-speciﬁc tariffs for the EQ-5D valuation system.
Methods
The initial target of this study was to identify all large general
population valuations studies employing the EQ-5D as the tool for
describing health. EMBASE and MEDLINE were searched for
such articles. To be considered for inclusion, the analysis had to
present primary research in English and be published since 1995.
Because it was expected that a proportion of good quality reports
may be unavailable in peer-reviewed publications, the reference
lists of articles identiﬁed in the main search were used to identify
further studies. Because all of these identiﬁed nonpeer-reviewed
publications were available on the EuroQol Web site (http://
www.euroqol.org), the list of EuroQol Plenary Meeting Proceed-
ings was scanned for further studies relevant to this work. To be
included, a study had to attempt to value all 243 states described
by the EQ-5D. Beyond this constraint, we chose to be conservative
in our approach to exclusion because we were seeking to identify
divergence in approach.
For each included study, details most relevant to the analysis
of the methods used were identiﬁed. Key areas for discussion
were selected. These areas were the precise formulation of the
algorithm, the number of states directly valued in the survey to
generate weights, the method to value states worse than death,
the inﬂuence of time preferences of results, and international
comparisons in predicted values across EQ-5D space.
The algorithms were compared by expanding the approach
used by Busschbach et al. [12], who compare the directly valued
states in the UK, Germany, and Spain. For this, Busschbach et al.
used the UK results as the benchmark. The predicted preference
scores for the states under the UK algorithm were then ranked in
descending order. The preference scores under each of the other
algorithms are generated by using the same ordering as in the UK
study. We extended this approach by including all identiﬁed
algorithms. Thus, we can identify any tendency for countries to
trade off quantity of life for quality of life, and identify whether
countries differ in their relative valuations of the ﬁve dimensions.
Results
10 articles [11,13–21] that met the inclusion criteria were iden-
tiﬁed, of which eight were published in peer-reviewed journals.
These are listed in Table 2. It should be noted that there are, at
present, no such results for Canada or Australia, two countries
strongly supportive of the use of CUA in health-care decision-
making. Two studies utilized the visual analog scale (VAS) as the
primary method of valuation [14,15]. Although this technique is
widely used in preference elicitation more generally, the age of
the two VAS studies in this area suggests that it has been super-
seded by the TTO although work by Parkin and Devlin suggests
that the VAS remains a valuable tool [22].
Three signiﬁcant methodological differences emerged regard-
ing the survey structure and the development of the algorithm.
The ﬁrst regarded the number of states that need to be directly
valued to estimate valuations for the complete EQ-5D space. The
second is the approach to valuing states considered to be worse
than death. The third is the choice of the algorithm to model
those states not directly valued. There were a number of addi-
tional issues that might also be considered such as the validity of
the TTO method and the assumption of constant proportional
trade-off that it is founded on. Nevertheless, it was felt that this
had been adequately covered elsewhere [23,24,25].
The Number of Directly Valued States
Given that the EQ-5D has 243 individual possible states, it is
unsurprising that no study has attempted to ask respondents to
directly value each of these states. Therefore, the pertinent ques-
tion becomes how best to form a representative fraction of the
entire space that allows a good estimation of the remainder of the
EQ-5D states in whichever way that is deﬁned. Two approaches
have been adopted to form this representative fraction. The
Table 1 The EQ-5D
Dimension Description
Mobility
1 I have no problem in walking about.
2 I have some problems in walking about.
3 I am conﬁned to bed.
Self-care
1 I have no problems with self-care.
2 I have some problems washing and dressing myself.
3 I am unable to wash and dress myself.
Usual Activities
1 I have no problems with performing my usual activities.
2 I have some problems with performing my usual
activities.
3 I am unable to perform my usual activities.
Pain/Discomfort
1 I have no pain or discomfort.
2 I have moderate pain or discomfort.
3 I have extreme pain or discomfort.
Anxiety/Depression
1 I am not anxious or depressed.
2 I am moderately anxious or depressed.
3 I am extremely anxious or depressed.
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original Dolan et al. approach valued 43 states, and each respon-
dent directly valued a subset of these 43 [9,26]. An alternative
approach (described here as the Tsuchiya approach), which uses
17 states, all rated by each respondent, was developed [11]. Both
sets of states are given in Table 3.
Lamers et al. [19] investigate these alternative approaches.
Using data from Dolan et al. [9], they assumed that all respon-
dents would value 11111 (full health) and in addition value
12,17,22,27,32,37 or 42 of the remaining 42 states. Samples of
size 50, 100, 200, 300, 400, 600, and 800 were assumed. The
outcome for each of these combinations is the mean absolute
error (MAE) between the predicted values from the subsequent
algorithm and the values observed in the data set. MAE is a
useful tool for estimating appropriateness because it shows the ﬁt
of the model to the data. Nevertheless, other diagnostics might
also be of value, for example, out-of-sample or split-sample
prediction (of directly valued states or otherwise).
As expected, the MAE is negatively associated with both the
sample size and the number of health states directly valued.
Additionally, they contrast these data with the results of Dolan
et al. [26], which suggest that not only does the 17-state
approach used by Tsuchiya et al. [11] lead to a lower MAE than
that of Dolan et al. but also it may lead to a lower MAE than if
each respondent valued 17 (or even 22) randomly assigned states
from the 42 (although the difference does not appear to be
statistically signiﬁcant). The mean correlation for the predicted
and actual values if 22 states from 42 are randomly selected is
0.986 (SD = 0.006), whereas the ﬁgures for the 17 states used by
Tsuchiya et al. was 0.989 (SD = 0.002).
A related question concerns whether the 17- and 43-state
approaches are optimal in terms of study design. For equal
precision in each of the effect estimates to be allowed, it is
necessary to have equal frequency of appearance for each of the
levels for each of the attributes. Because there is a disproportionate
number of the better health states, that is, states with attributes at
level 1, in the 43 Dolan states [9] or the 17 Tsuchiya states [11],
there is greater precision at that healthy end of the scale. The other
related issue involves the estimation of interactions. Although
only 10 degrees of freedom are required for the estimation of main
effects, a further 40 are required to estimate two-factor interac-
tions. Of course, if certain level combinations do not appear
together (and perhaps do not make sense together), then estima-
tion of all two-factor interactions becomes impossible.
Transformation of Values for Worse than Dead States
Although it is plausible that the poorer states in the EQ-5D might
be considered worse than immediate death, certain methodologi-
cal issues arise from generating an algorithm with a subset of
states that includes states worse than death. While anchoring
death at 0 and full health at 1 gives meaning to states that lie in
that range, it is difﬁcult to interpret different values below 0. The
lack of a tool that is well suited to this task means that existing
articles have taken a variety of approaches to valuing these states,
some of which raise further questions.
All articles begin from the same starting point, by asking
respondents to choose between immediate death and a period of
10 years of life, some of which is spent in the state worse than
death and some in full health. In the majority of articles
[11,13,16,17,19,21], if the individual is indifferent between
immediate death and x years of the bad state followed by
(10 - x) years of full health, the score for the state worse than
death is then calculated in the following way:
Preference score State worse than death( ) = ( ) −x 10 1 (1)Ta
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Because x is bounded by 0 and 10, the preference scores for states
worse than death are bounded by 0 and -1. The one divergence
from this orthodoxy is found in Shaw et al. [20], for whom
Preference score State worse than death( ) = −( )x x10 (2)
They allowed the value for x to be between 0.25 and 9.75 years,
meaning that the preference score is initially as low as -39. This
leads to an asymmetry between states better than immediate
death and those worse. This is important because it means that
the impact of a brief period in the severest health state is of the
same magnitude as a much longer period in full health. Although
a poor state such as this might be plausible, it could be argued
that the uncertainty surrounding interpretation of states worse
than death means that the value we place on these states should
not have a dominant inﬂuence on the ﬁnal algorithm. Shaw et al.
suggested that states worse than death should be bounded by -1.
Thus, they applied a linear transformation to the raw scores,
constraining all scores to be in this range [20]. The major
problem with this linear transformation is that the valuations in
this range are dependent on the minimum length of time the
respondent is allowed to endure in the bad health state. If the
minimum period allowable in the poor health state increases to,
for example, 1 year, all negative values would be divided by nine.
The effect of dividing the different health valuations by different
factors (deﬁned by the shortest allowable period in the poor
health state) is illustrated in Figure 1.
As health moves away from 0 toward -1, the effect of this
procedural variable becomes increasingly large and suggests that
this divergence from the orthodox position is not justiﬁed.
The Construction of the Algorithm
The choice of the algorithm is intrinsically associated with the
states directly valued in the TTO. Equal precision around point
estimates of main effects depends on equal appearance frequency
for each of the levels, which does not occur in the states valued in
any of the international articles. Equally, for interactions between
levels to be estimated, most of which are plausible, these interac-
tions have to appear in the states directly valued, which certainly
are not the case for all pairs of levels. In choosing an algorithm, the
benchmark UK study [16] prefers the N3 model, in which the
algorithm is a main effects model using dummy variables for levels
in each dimension worse than “No Problems,” plus the N3
dummy variable, deﬁned as 1 when any of the dimensions are
at level 3 (the worst level). Thus, Valuation = 1 - [constant +
S(dummyl,d * co-efﬁcientl,d) + (dummyN3 * coefﬁcientN3)].
Aside from increased predictive value of the model with this
interaction term [9], the intuition behind using such a value is
not clear. Indeed, the Japanese data showed no improvement in
model ﬁt after inclusion of the N3 term. One potential expla-
nation for including the N3 term is that the ﬁrst dimension
moving to level 3 will have signiﬁcant spillover effects, perhaps
not captured by the other dimensions. The need to adapt to a
life with a severe impediment has a disutility that is a one-off.
Thus, the second dimension to move to level 3 will have a
disutility (illustrated by the coefﬁcient associated with the
respective dummy variable) but may have a lesser impact than
if the move had occurred from a state with no pre-existing level
3 problems. The reverse argument, claiming that the N3 term
has no intuitive appeal, might argue that the extra predictive
value is a remnant of the correction methods used to adjust
states worse than death to constrain them between 0 and -1.
Because these states are considerably more likely to have level
3 dimensions than the general set of states, it is arguable that
applying an erroneous transformation, compressing negative
values into too small a range, might be identiﬁed through lower
coefﬁcients being applied to level 3 parameters beyond the
ﬁrst.
Table 3 The states selected by Dolan and Tsuchiya et al. (common states in bold)
Category Tsuchiya Dolan (the number valued by each respondent is in parentheses)
Full health 11111 11111
Very mild 11112, 11121, 11211, 12111, 21111 (2 from 5) 11112, 11121, 11211, 12111, 21111
Mild 11113, 11131, 11133, 11312 (3 from 12) 11122, 11131, 11113, 21133, 21222, 21312, 12211, 11133, 22121, 12121, 22112, 11312
Moderate 13311, 32211, 32313, 22222 (3 from 12) 13212, 32331, 13311, 22122, 12222, 21323, 32211, 12223, 22331, 21232, 32313, 22222
Severe 23232, 32223, 33323 (3 from 12) 33232, 23232, 23321, 13332, 22233, 22323, 32223, 32232, 33321, 33323, 23313, 33212
Pits state 33333 33333
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Figure 1 The effect of changing minimum time
duration on valuations of states worse than death.
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Other than the N3 variable, most studies do not utilize inter-
action terms in their ﬁnal models. Nevertheless, the intuitive
argument in support of interactions can be illustrated by using a
number of examples (e.g., the disutility of not being able to do
usual activities may vary, depending on whether the person is
mobile because this deﬁnes what usual activities consist of). A
number investigate alternative model speciﬁcations containing
interactions [19] but generally (and perhaps surprisingly) ﬁnd
that they do not improve the ﬁt of the model [11,13,16,21].
The ﬁnal issue regarding the algorithm is the use and inter-
pretation of the constant term. Conventionally, the intercept
reﬂects the value of the function when all explanatory variables
are 0 (level 1 in the N3 model). Nevertheless, in this case, this
interpretation does not hold because 11111 is axiomatically
described as full health and is anchored at 1. In the identiﬁed
articles, there are two approaches in the discussion of the inter-
cept. In the majority of studies, the intercept is allowed to vary
from 0 and is interpreted as the disutility associated with not
being at perfect health, independent of the disutility associated
with the movement within the dimension per se [10]. This could
be justiﬁed in the same way as the N3 variable was justiﬁed
above. An alternative approach is taken in a recent US study [20].
The full algorithm used in this study is given by
Valuation dummy coefficient D
I -squared
l d l d= − ∗( ) + +(
+
1 1
2
1
2
Σ , , β
β β β3 43 3I I -squared ,+ ) (3)
where D1 is the number of dimensions not at level 1 beyond the
ﬁrst, I2 is the number of dimensions at level 2 beyond the ﬁrst,
and I3 is the number of dimensions at level 3 beyond the ﬁrst.
The differences between this approach and the more commonly
utilized N3 approach are that Shaw et al. [20] do not allow a
constant term (because full health is anchored at 1) and that they
identiﬁed a broader group of statistically signiﬁcant interaction
terms, albeit speciﬁed in a different way. One criticism of both
approaches is that they are relatively blunt in their approach to
interactions. For example, if we consider the interactions con-
cerning dimensions being at level 3, the effect of there being a
number of dimensions at level 3 is independent of the speciﬁc
dimensions at that level.
International Comparisons
The ﬁnal question this article considers is the extent to which the
use of these different algorithms affects the preference scores
associated with the 243 states in EQ-5D space and, thus, whether
the choice of model is likely to alter resource allocation decisions.
Our results, comparing the wider range of countries using all
states deﬁned by EQ-5D space, are shown in Figures 2 and 3
(note that the UK algorithm is smooth because it has been
selected as the base case).
We have compared the algorithms to the benchmark in
groups of three. When algorithms from Denmark, Germany, and
The Netherlands are compared with the UK study, they generate
similar preference scores across the range of health states. Gen-
erally, these lie above the UK ﬁgures but follow the same trend.
This suggests that the various dimensions of the EQ-5D have the
same approximate relative importance in these countries, but the
absolute disutility attached to worsening in the health state in
general is estimated to be lower. Regarding the apparent ten-
dency for the UK algorithm to provide health state valuations
that are lower than those for other algorithms, it is worth noting
that a modiﬁed Research Group on the Measurement and
Valuation of Health protocol was used in a repeat experiment in
a UK population [27], which produced scores generally higher
than those derived from the Dolan et al. algorithm [27].
Divergence from this trend can be seen in the countries
shown in Figure 3. The Spanish model does not appear to be
systematically different from the UK model but displays more
variance from the UK model than the Northern European
results, suggesting different emphasis between dimensions. The
Japanese results are less than those of all other models for mild
health states (as a result of a large constant term in the N3
model) but, for worse states, lie above all other models. Under
the Japanese model, there are very few states considered worse
than death. Additionally, the Japanese results show considerable
variance relative to the UK ﬁgures. In comparing the Japanese
results with the UK, this seems to be the result of a relatively
high importance being associated with mobility and a relatively
low importance being associated with pain and discomfort, and
anxiety and depression. The US study follows a similar pattern
to the Japanese results but displays less variability relative to the
UK. This unwillingness to trade off quantity of life for quality of
life in Japan and the US means that the spread of HRQoL scores
is lower in these countries. As noted by Luo et al. and Noyes
et al., this will lead to interventions being less cost-effective in
CUA because the quality of life gain is likely to be smaller
[28,29].
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algorithms.*
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The uncertain element in interpreting these results is to identify
whether the differences in models are a result of genuine differ-
ences in national attitudes toward ill health or whether they are the
product of different study designs (including any difference caused
by translation issues). In support of the former is the fact that
Figure 2 suggests convergence between countries in a geographic
locality (Northern Europe). Nevertheless, we believe that to ﬁrmly
identify a trend in models between countries, we would require a
greater number of studies than currently exist, preferably using
data collected by using the same mechanism and at the same time
point. The analysis of subgroups within a population is also of
potential interest because it may identify what drives health state
valuation patterns, both within a population and potentially
between populations. Potential explanatory factors might include
wealth, income, religion, or health expenditure.
Conclusions
This article identiﬁes a number of key methodological questions
in the construction of population-level EQ-5D/TTO value sets.
The number of states that need to be directly valued is consid-
ered, and the best solution may depend on whether it is worth-
while to look for interaction terms. We identiﬁed study design
issues with the sets of states most commonly selected to be
directly valued. The decision regarding number of states leads
into a number of questions regarding the choice of algorithm.
Then, we identiﬁed competing approaches for the valuation of
states considered to be worse than death and identiﬁed that the
approach used by Shaw et al. [20] makes valuations heavily
dependent on a parameter of model design (speciﬁcally the
minimum period of the state considered in the TTO) that should
have no effect on the valuation.
Whether country-speciﬁc algorithms are necessary is a difﬁcult
question that we have only partly addressed. There are clear
divergences between countries in their valuations, in terms of both
their willingness to trade quantity of life for quality and their
relative importance of the ﬁve dimensions of the EQ-5D. Our
ﬁndings indicate that a proportion of the divergences in algo-
rithms are likely to be attributable to genuine cultural differences
rather to than methodological differences between studies, which
suggests that country-speciﬁc algorithms are of importance. This
is particularly true in countries that engage in substantial eco-
nomic evaluation such as Canada and Australia, which are cur-
rently reliant on using algorithms derived from countries asserted
to be comparably similar in terms of attitude to health.
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